Patents by Inventor Gonzalo Alva

Gonzalo Alva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for making a solid-state form of AMG 706
    Patent number: 8648199
    Abstract: The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: February 11, 2014
    Assignee: Amgen Inc.
    Inventors: Belle Bei Liu, Nina Cauchon, Gonzalo Alva, Pengzu Zhou
  • PROCESS FOR MAKING A SOLID-STATE FORM OF AMG 706
    Publication number: 20130317227
    Abstract: The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 28, 2013
    Applicant: Amgen Inc.
    Inventors: Belle Bei Liu, Nina Cauchon, Gonzalo Alva, Pengzu Zhou
  • Hydrate forms of AMG706
    Patent number: 7989631
    Abstract: The anti-angiogenic drug AMG 706 is provided in the mono-phosphate hydrate form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as AMG 706 phosphate dihydrate. Also provided are processes for preparing AMG 706 phosphate dihydrate, AMG 706 drug substance of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 2, 2011
    Assignee: Amgen Inc.
    Inventors: Gonzalo Alva, Seshadri Neervannan
  • SOLID-STATE FORM OF AMG 706 AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20100331548
    Abstract: The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Application
    Filed: September 3, 2010
    Publication date: December 30, 2010
    Applicant: Amgen Inc.
    Inventors: Belle B. Liu, Gonzalo Alva, Nina Cauchon, Seshadri Neervannan, Pengzu Zhou
  • Polymorphic Form of -Acetic Acid
    Publication number: 20090012133
    Abstract: The present invention relates to a novel polymorphic form of the compound {2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylthio]phenoxy}-acetic acid, methods of preparing it, pharmaceutical compositions and medicaments containing the same, and use of such polymorphs, compositions and medicaments in the treatment of PPAR mediated diseases or conditions.
    Type: Application
    Filed: January 10, 2007
    Publication date: January 8, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventor: Gonzalo Alva
  • Solid-state form of AMG 706 and pharmaceutical compositions thereof
    Publication number: 20080108664
    Abstract: The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.
    Type: Application
    Filed: December 7, 2006
    Publication date: May 8, 2008
    Inventors: Belle B. Liu, Gonzalo Alva, Nina Cauchon, Seshadri Neervannan, Pengzu Zhou
  • HYDRATE FORMS OF AMG706
    Publication number: 20080039501
    Abstract: The anti-angiogenic drug AMG 706 is provided in the mono-phosphate hydrate form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as AMG 706 phosphate dihydrate. Also provided are processes for preparing AMG 706 phosphate dehydrate, AMG 706 drug substance of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 14, 2008
    Applicant: Amgen Inc.
    Inventors: Gonzalo Alva, Seshadri Neervannan